아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - lacosamidum inn - filmuhúðuð tafla - 100 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - lacosamidum inn - filmuhúðuð tafla - 200 mg

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - lacosamidum inn - filmuhúðuð tafla - 50 mg

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - Æxlishemjandi lyf - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

pharmaxis europe limited - mannitól - cystic fibrosis - hósti og kuldablöndur - bronchitol er ætlað til meðferðar við blöðrubólgu (cf) hjá fullorðnum 18 ára og eldri sem viðbótarmeðferð við bestu umönnun.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - Ónæmisbælandi lyf - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

le vet b.v.* - xylazinum hýdróklóríð - stungulyf, lausn - 100 mg/ml

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn; formoterolum fúmarat - innöndunarduft - 320/9 míkróg/skammt

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn; formoterolum fúmarat - innöndunarduft - 80/4,5 míkróg/skammt

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn; formoterolum fúmarat - innöndunarduft - 160/4,5 míkróg/skammt